WILGO RESEARCH INDEX
BPC-157
BPC-157 is a 15-amino-acid peptide investigated primarily in preclinical models involving tissue repair, gastrointestinal injury, vascular signaling, and wound healing. Human evidence exists, but it remains extremely limited and is not comparable in strength to the animal and mechanistic literature.
15 amino acids
Tissue research
Gastrointestinal models
Angiogenesis research
Human evidence: very limited
EVIDENCE MAP
What kind of evidence exists?
The key distinction is model quality. A positive finding in cultured cells or a rat injury model is not evidence of established safety or efficacy in humans.
The strongest conclusion from the literature is about uncertainty.
BPC-157 has a broad preclinical literature, but current human evidence is too sparse to establish clinical effectiveness, long-term safety, or a validated therapeutic regimen. This page therefore reports study findings by model rather than presenting them as human benefits.
PUBLISHED LITERATURE
Selected studies.
These studies were selected to represent the major evidence categories rather than to imply that every published paper is equally strong.
HUMAN · RETROSPECTIVE
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
A retrospective chart review contacted 16 patients after knee injections. Twelve had received BPC-157 alone; 11 of those 12 reported significant improvement. The study lacked a control group, standardized outcome instruments, imaging confirmation, and consistent follow-up, so it should be treated as low-level observational evidence rather than proof of efficacy.
HUMAN · PILOT SAFETY
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
This IRB-approved pilot involved only two adults who received intravenous BPC-157 on consecutive days. The investigators reported no measured adverse effects in the tested biomarkers and no reported side effects. The sample size is far too small to establish general safety, uncommon adverse events, long-term safety, or clinical efficacy.
PRECLINICAL · TENDON / CELL MECHANISM
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Using rat Achilles-tendon explants and tendon fibroblasts, the study reported greater explant outgrowth, improved cell survival under oxidative stress, and increased cell migration with BPC-157 treatment. It did not show a direct increase in fibroblast proliferation.
PRECLINICAL · TENDON-TO-BONE
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157
In a rat Achilles tendon-to-bone detachment model, investigators reported improved healing-related outcomes with BPC-157 and studied its interaction with corticosteroid-associated impairment. This is animal-model evidence and does not establish a corresponding clinical effect in people.
PRECLINICAL · GASTRIC INJURY
Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats
Across induced acute and chronic gastric-ulcer models in rats, the study reported reductions in ulcer area and changes consistent with accelerated healing in BPC-157-treated groups. These findings belong to experimental gastric-injury models and cannot be interpreted as established treatment efficacy in humans.
PRECLINICAL · ANGIOGENESIS
Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing
Using cell culture plus injured muscle and tendon models, investigators evaluated VEGF-related angiogenesis. The authors reported no direct angiogenic effect in the cell-culture component, while treated animal tissues showed altered angiogenesis markers associated with healing.
MECHANISTIC · VEGFR2
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
In endothelial-cell assays and a rat hind-limb ischemia model, the study reported increased vessel-related measures and changes in VEGFR2 expression and internalization. This provides mechanistic evidence for angiogenesis-related signaling, not clinical proof of tissue healing in humans.
MECHANISTIC · WOUND MODEL
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro
The study combined an alkali-burn wound model with human umbilical-vein endothelial-cell experiments. Investigators reported changes in VEGF expression, endothelial migration, vascular-tube formation, and ERK1/2-related signaling. The experimental design remains preclinical.
MECHANISTIC · 2026
BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1
This 2026 molecular study investigated protein interactions, ubiquitination, and endothelial functions related to the pro-angiogenic effects of BPC157. It adds mechanistic detail to the vascular-signaling literature but does not itself provide evidence of clinical benefit.
SYSTEMATIC REVIEW · 2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
The review screened literature through 2024 and included 36 studies: 35 preclinical studies and one clinical study. It found a strong imbalance between preclinical and human evidence and emphasized that clinical safety and effectiveness remain inadequately established.
REVIEW · 2026
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
This recent review concludes that, despite extensive preclinical activity, BPC-157 lacks an approved formulation, validated dosing regimen, and completed Phase II evidence base sufficient for clinical advancement. It highlights major formulation, pharmacokinetic, safety, and regulatory uncertainties.
REGULATORY CONTEXT
Current status matters.
Research interest is not the same thing as regulatory approval. The distinction should remain explicit on a research-reference page.
U.S. FDA
FDA materials presented to the Pharmacy Compounding Advisory Committee in July 2026 state that BPC-157 is not a component of an approved product in any country and describe concerns about physicochemical characterization, safety information, immunogenicity, and evidence of effectiveness. FDA proposed against adding BPC-157 free base and acetate to the 503A Bulks List.
FDA SOURCE →World Anti-Doping Agency
The 2026 WADA Prohibited List names BPC-157 under S0 Non-Approved Substances, meaning it is prohibited at all times for athletes subject to the World Anti-Doping Code.
WADA 2026 LIST →CHEMISTRY & IDENTIFIERS
Verified compound data.
Chemical identifiers below are taken from PubChem and FDA/NIH substance records rather than copied from commercial peptide websites.
PubChem
PubChem CID 9941957 lists BPC-157 with molecular formula C62H98N16O22, molecular weight 1419.5 g/mol, CAS 137525-51-0, and sequence GEPPPGKPADDAGLV.
PUBCHEM →FDA / GSRS
The FDA substance record identifies BPC-157 under UNII 8ED8NXK95P and records the 15-residue sequence GEPPPGKPADDAGLV. The substance hierarchy separately recognizes BPC-157 acetate as a salt/solvate.
FDA SUBSTANCE RECORD →REFERENCES
Primary sources.
WILGO links readers to the original publication or authoritative regulatory record wherever practical.
PubChem. BPC-157, CID 9941957.Open source →
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.PMID 34324435 · PubMed →
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.PMID 40131143 · PubMed →
Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.PMID 21030672 · DOI 10.1152/japplphysiol.00945.2010 · PubMed →
Krivic A et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157.PMID 16583442 · DOI 10.1002/jor.20096 · PubMed →
Xue XC et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.PMID 15052688 · PMCID PMC4717094 · DOI 10.3748/wjg.v10.i7.1032 · PubMed →
Brcic L et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.PMID 20388964 · PubMed →
Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.PMID 27847966 · PubMed →
Huang T et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.PMID 25995620 · PubMed →
Zhang J et al. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1.PMID 41606641 · PubMed →
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.PMID 40756949 · PubMed →
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.PMID 42198317 · PubMed →
Research-use notice: This resource summarizes published scientific literature for informational and research-reference purposes. It does not provide medical advice, dosing, reconstitution, injection, therapeutic, diagnostic, or other human-use instructions. WILGO products are intended for laboratory research use only and are not presented for human or animal consumption, diagnosis, treatment, prevention, weight management, cosmetic use, or self-administration.